|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Antithrombin III Activity
MessageMust be collected only at the following locations:
Duke Street Lab Testing
Suburban Pavilion Lab Testing
Women and Babies' Hospital Lab Testing
Duke Street Lab Testing
Suburban Pavilion Lab Testing
Women and Babies' Hospital Lab Testing
Test Code
216
Alias/See Also
Z0779
Anti-Thrombin III Activity
LAB3020492
Anti-Thrombin III Activity
LAB3020492
CPT Codes
85300
Preferred Specimen
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Instructions
Please submit a separate, frozen vial for each special coagulation assay ordered.
Platelet poor plasma: Centrifuge light blue-top tube 15 minutes at approx. 1500 x g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid the wbc/platelet buffy layer, and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (< 10,000/mcL). Freeze immediately and ship on dry ice.
Platelet poor plasma: Centrifuge light blue-top tube 15 minutes at approx. 1500 x g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid the wbc/platelet buffy layer, and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (< 10,000/mcL). Freeze immediately and ship on dry ice.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 30 days
Refrigerated: Unacceptable
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Received thawed • Received refrigerated
Methodology
Chromogenic Substrate
Setup Schedule
Set up: Mon-Fri; Report available: Next day
Limitations
Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: no effect; Heparin (UFH or LMWH): no effect to decrease (UFH may decrease levels physiologically but no assay interference); Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase; Rivaroxaban or Apixaban (Factor Xa Inhibitors): no effect.
Reference Range
| 1 day-1 month | 41-108 % normal |
| 31 days-2 months | 50-120 % normal |
| 3-5 months | 73-120 % normal |
| ≥6 months | 80-135 % normal |
Clinical Significance
Aids in the detection of hypercoagulable states associated with venous thrombotic episodes. May be useful in patients who appear to be hyporesponsive to heparin.
